Sentences with phrase «vaccine antigens for»

This «suggests that antibodies specific for this conserved region could provide protection against multiple toxin - mediated clostridium infections and points to a generalizable strategy for generating safe vaccine antigens for this class of toxins,» they concluded.

Material (i.e. vaccine) suitable for preclinical in vivo immunisation studies and vaccine antigen for the assays will be provided by the user.

Not exact matches

Secondly, it helps improve the immunogenicity of some vaccines, which is the body's ability to produce antibodies against the antigen for which the vaccine has been given.

The study size requires screening about 10,000 patients for the presence of the MAGE - A3 antigen that the vaccine targets.

The United States, for example, ordered $ 649 million of pandemic H1N1 influenza vaccine antigen and $ 283 million of adjuvant on May 22, 2009.

The findings underscore the need for targeted research to further evaluate manufacturing strategies and vaccine antigens and platforms, according to the authors.

«Mechanism for inducing memory B cell differentiation elucidated: Efficient induction of immune cells that remember antigens will lead to the development of new vaccines.»

For the study, the research team used a new method in which mice were immunized with a model vaccine (called an antigen) that is given orally.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

«Because GAC is present in all strep strains, this may represent a safer antigen for inclusion in a universal strep vaccine.»

Nirbhay Kumar, a molecular biologist at the Johns Hopkins School of Public Health in Baltimore, wondered whether injecting the genes for the Plasmodium antigens would work as a vaccine.

Together with a partner from the industry, the research team successfully tested a vaccine from a new AAV mimotope library for a tumour antigen of breast cancer, the growth factor HER2.

Cornell and Ludwig Institute for Cancer Research scientists have developed a way to produce a protein antigen that may be useful as vaccine for schistosomiasis — a parasitic disease that infects millions of people, mostly in tropical and subtropical climates — according to new research in the journal Protein Expression and Purification, June 2017.

By contrast, the neoantigen vaccine is custom - made for each patient using antigens produced by mutations unique to the patient's cancer and only present on cancer cells, thus bypassing the nature immune tolerance process.

Commercial arrays are not available for all biomarkers, so customised arrays for the analysis of vaccine candidates will be developed, featuring antigens for direct detection or antibodies for sandwich immunoassays (e.g. for cytokine detection).

The Center has a GMP pilot plant being able to produce recombinant antigens for vaccine formulations, formulation studies with the SSI CAF cased adjuvants is performed in laboratories using qualified equipment and procedures.

TNA4: Production of recombinant antigens and final formulated vaccines for toxicological studies

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

Research will aim to improve the predictive value of animal models for vaccine evaluation, provide consultancy on the selection of appropriate models, and develop innovative approaches to characterise in vivo antigen behaviour and host responses whilst reducing animal use.

Firstly, it will develop optimised viral vectors suitable for expressing antigens from a range of different diseases, to create novel vaccines.

vector - a bacterium or virus that does not cause disease in humans and is used in genetically engineered vaccines to transport genes coding for antigens into the body to induce an immune response.

Results will be compared with new ex vivo / in vitro approaches for testing innate and adaptive responses induced by vaccine antigens.

Currently, pDNA can be used directly as a therapeutic agent (e.g., in gene therapy or generation of vaccine antigens) and indirectly for a range of applications.

«Paradoxically, the study does offer some good news for those working on live vaccines or live vaccine vectors because these are not just vaccine antigens but organisms in their own right that necessarily manipulate host responses (such as those involving IL28B) for their own survival.

Competing interests: SD and DEL hold patents for the FMP2.1 vaccine antigen.

His ongoing research projects include programs to develop adjuvants for use with H5N1 pandemic influenza antigens as well as West Nile Virus vaccines.

Recombinant Deoxyribonucleic Acid (DNA) vaccines contain some or all of the gene (s) for expression of the antigen (s) within a suitable molecule.

Robert Schoen, M.D., M.P.H., of the University of Pittsburgh, presented research showing that the tumor - associated antigen MUC1 is a promising target for such a preventative vaccine.

The department has developed and produced 15 different formulations for early clinical trials (e.g. vaccine antigens produced by heterologous expression) and has conducted more than 20 clinical trials as sponsor.

Overall, this study both identifies specific antigen combinations for high - priority clinical testing and establishes a generalizable approach that is more likely to produce effective vaccines.

«The question now is, can the nanoparticles be effective delivery vehicles for vaccines or be used for for co-delivery of antigens and adjuvants?

These events relate primarily to settlement of VaxGen's obligations under its lease of facilities in South San Francisco, and to the potential award of a procurement contract to Emergent BioSolutions (NYSE: EBS) by the U.S. Government for which VaxGen is eligible to receive milestone and royalty payments in connection with Emergent BioSolutions» May 2008 acquisition of VaxGen's recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology.

By using the three - year vaccine, the body is challenged less often by these antigens, which minimizes the total risk for vaccine reactions, and also minimizes the number of injections over a pet's lifetime.»

Vaccines contain only a small amount of antigen for safety reasons; you wouldn't want your dog to get rabies from the vaccine!

This provides the basis for increasing immunity by further repeated exposure to these antigens either through natural exposure in small doses or artificial exposure with vaccines during the next 8 to 12 weeks.

These include pain and stinging at the injection site, swelling (inflammation of surrounding tissue) and vasculitis (inflammation of blood vessels) and are not caused by the antigen itself being administered but rather by the conditions surrounding its administration (for example, temperature of the vaccine or inactive ingredients in the vaccine).

LEUKOCELL 2 is a multiple viral antigen vaccine for vaccination of healthy cats 9 weeks of age or older as an aid in preventing persistent viremia, lymphoid tumors caused by feline leukemia virus (FeLV) and diseases associated with FeLV infection.

The most commonly used vaccine against panleukopenia, herpesvirus and calicivirus is a multivalent vaccine: it contains viral antigens for several diseases together in the same dose, and is commonly abbreviated as the «FVRCP» vaccine.

The actual antigen in each dose is small and typically safe for all dogs, but in order for the vaccine to protect a dog for a whole year it also contains some toxic ingredients.

I have no commercial interest in any of these companies nor any experience purchasing anything from them or using their products; they are simply resources for single - antigen vaccines of which I've been made aware.

Each vaccine contains antigens for a specific disease, and the vaccine resembles the organism of the disease it protects against.

These results suggest that tumor antigen loaded CD40 - B may serve as a practical alternative to DC in cell - based vaccine strategies for both dogs and humans with cancer.